{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T13:40:10Z","timestamp":1742218810412,"version":"3.38.0"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Changzhou Science and Technology Program","award":["nos.: CM20223005","CJ20242023"],"award-info":[{"award-number":["nos.: CM20223005","CJ20242023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s43440-024-00693-3","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T16:34:24Z","timestamp":1737477264000},"page":"333-354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tacrolimus and diabetic rodent models"],"prefix":"10.1007","volume":"77","author":[{"given":"Minyan","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengmeng","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7505-5001","authenticated-orcid":false,"given":"Nan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"issue":"4","key":"693_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1517\/14656566.9.4.635","volume":"9","author":"LJ Bowman","year":"2008","unstructured":"Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantation. Expert Opin Pharmacother. 2008;9(4):635\u201343.","journal-title":"Expert Opin Pharmacother"},{"key":"693_CR2","doi-asserted-by":"crossref","unstructured":"World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization; 2021. Contract No.: WHO\/MHP\/HPS\/EML\/2021.02.","DOI":"10.1530\/ey.19.13.1"},{"issue":"7","key":"693_CR3","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1016\/S0041-1345(99)00589-8","volume":"31","author":"MA Manu","year":"1999","unstructured":"Manu MA, Tanabe K, Ishikawa N, Tokumoto T, Oshima T, Shinmura H, et al. Tacrolimus rescue for resistant rejection, chronic rejection, and immunoglobulin A nephropathy of renal allografts under primary cyclosporine A immunosuppression. Transplant Proc. 1999;31(7):2853\u20135.","journal-title":"Transplant Proc"},{"issue":"4","key":"693_CR4","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0041-1345(98)00226-7","volume":"30","author":"S Friemann","year":"1998","unstructured":"Friemann S, Feuring E, Padberg W, Ernst W. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Transplant Proc. 1998;30(4):1240\u20132.","journal-title":"Transplant Proc"},{"issue":"8","key":"693_CR5","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2337\/diab.37.8.1129","volume":"37","author":"AA Sima","year":"1988","unstructured":"Sima AA, Zhang WX, Tze WJ, Tai J, Nathaniel V. Diabetic neuropathy in STZ-induced diabetic rat and effect of allogeneic islet cell transplantation. Morphometric analysis. Diabetes. 1988;37(8):1129\u201336.","journal-title":"Diabetes"},{"issue":"8","key":"693_CR6","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2337\/dc08-1685","volume":"32","author":"MC Vantyghem","year":"2009","unstructured":"Vantyghem MC, Kerr-Conte J, Arnalsteen L, Sergent G, Defrance F, Gmyr V, et al. Primary graft function, metabolic control, and graft survival after islet transplantation. Diabetes Care. 2009;32(8):1473\u20138.","journal-title":"Diabetes Care"},{"issue":"3","key":"693_CR7","first-page":"1034","volume":"24","author":"WJ Tze","year":"1992","unstructured":"Tze WJ, Tai J, Cheung SS, Ricordi C, Murase N, Starzl TE. FK 506\u2014an effective immunosuppressant in achieving long-term functional islet allograft survival in diabetic rats. Transplant Proc. 1992;24(3):1034\u20136.","journal-title":"Transplant Proc"},{"issue":"2","key":"693_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/0026-0495(94)90234-8","volume":"43","author":"WJ Tze","year":"1994","unstructured":"Tze WJ, Tai J, Cheung SS, Murase N, Starzl TE. Successful islet allotransplantation in diabetic rats immunosuppressed with FK506: a functional and immunological study. Metabolism. 1994;43(2):135\u20139.","journal-title":"Metabolism"},{"issue":"11","key":"693_CR9","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1517\/17425255.2014.964205","volume":"10","author":"EB Rangel","year":"2014","unstructured":"Rangel EB. Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions. Expert Opin Drug Metab Toxicol. 2014;10(11):1585\u2013605.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"693_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/00007890-200001270-00012","volume":"69","author":"ML Jordan","year":"2000","unstructured":"Jordan ML, Chakrabarti P, Luke P, Shapiro R, Vivas CA, Scantlebury VP, et al. Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. Transplantation. 2000;69(2):265\u201371.","journal-title":"Transplantation"},{"issue":"6","key":"693_CR11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2165\/00003495-199754060-00009","volume":"54","author":"CM Spencer","year":"1997","unstructured":"Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs. 1997;54(6):925\u201375.","journal-title":"Drugs"},{"issue":"1","key":"693_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1210\/er.2015-1084","volume":"37","author":"V Shivaswamy","year":"2016","unstructured":"Shivaswamy V, Boerner B, Larsen J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev. 2016;37(1):37\u201361.","journal-title":"Endocr Rev"},{"issue":"2","key":"693_CR13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1034\/j.1600-6143.2003.00010.x","volume":"3","author":"BL Kasiske","year":"2003","unstructured":"Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3(2):178\u201385.","journal-title":"Am J Transplant"},{"issue":"1","key":"693_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2337\/dc11-1230","volume":"35","author":"L Ghisdal","year":"2012","unstructured":"Ghisdal L, Van Laecke S, Abramowicz MJ, Vanholder R, Abramowicz D. New-onset diabetes after renal transplantation: risk assessment and management. Diabetes Care. 2012;35(1):181\u20138.","journal-title":"Diabetes Care"},{"issue":"2","key":"693_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.transproceed.2013.11.141","volume":"46","author":"LC Weng","year":"2014","unstructured":"Weng LC, Chiang YJ, Lin MH, Hsieh CY, Lin SC, Wei TY, et al. Association between use of FK506 and prevalence of post-transplantation diabetes mellitus in kidney transplant patients. Transplant Proc. 2014;46(2):529\u201331.","journal-title":"Transplant Proc"},{"issue":"4","key":"693_CR16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1399-3046.2005.00334.x","volume":"9","author":"G Filler","year":"2005","unstructured":"Filler G, Webb NJ, Milford DV, Watson AR, Gellermann J, Tyden G, et al. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion. Pediatr Transplant. 2005;9(4):498\u2013503.","journal-title":"Pediatr Transplant"},{"issue":"4","key":"693_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1046\/j.1600-6143.2003.00372.x","volume":"4","author":"O Heisel","year":"2004","unstructured":"Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004;4(4):583\u201395.","journal-title":"Am J Transplant"},{"issue":"12 Suppl 3","key":"693_CR18","doi-asserted-by":"publisher","first-page":"S291","DOI":"10.1681\/ASN.2006080929","volume":"17","author":"E Rodrigo","year":"2006","unstructured":"Rodrigo E, Fernandez-Fresnedo G, Valero R, Ruiz JC, Pinera C, Palomar R, et al. New-onset diabetes after kidney transplantation: risk factors. J Am Soc Nephrol. 2006;17(12 Suppl 3):S291\u2013S295.","journal-title":"J Am Soc Nephrol"},{"issue":"5 Suppl 6","key":"693_CR19","first-page":"89","volume":"19","author":"MA Nalesnik","year":"1987","unstructured":"Nalesnik MA, Todo S, Murase N, Gryzan S, Lee PH, Makowka L, et al. Toxicology of FK-506 in the Lewis rat. Transplant Proc. 1987;19(5 Suppl 6):89\u201392.","journal-title":"Transplant Proc"},{"issue":"3","key":"693_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, Asberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261\u2013307.","journal-title":"Ther Drug Monit"},{"issue":"10","key":"693_CR21","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/bies.20644","volume":"29","author":"JJ Heit","year":"2007","unstructured":"Heit JJ. Calcineurin\/NFAT signaling in the beta-cell: from diabetes to new therapeutics. BioEssays. 2007;29(10):1011\u201321.","journal-title":"BioEssays"},{"issue":"4","key":"693_CR22","first-page":"390","volume":"27","author":"A Aldieri","year":"2022","unstructured":"Aldieri A, Bae E, Chandran MM. Effect of jejunal administration on tacrolimus trough concentrations in a pediatric liver transplant recipient. J Pediatr Pharmacol Ther. 2022;27(4):390\u20135.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"9","key":"693_CR23","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/00007890-200105150-00021","volume":"71","author":"S Tuteja","year":"2001","unstructured":"Tuteja S, Alloway RR, Johnson JA, Gaber AO. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation. 2001;71(9):1303\u20137.","journal-title":"Transplantation"},{"issue":"10","key":"693_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"CE Staatz","year":"2004","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623\u201353.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"693_CR25","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/jcpt.12523","volume":"42","author":"HJ Zhang","year":"2017","unstructured":"Zhang HJ, Li DY, Zhu HJ, Fang Y, Liu TS. Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients. J Clin Pharm Ther. 2017;42(4):425\u201332.","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"693_CR26","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1373\/clinchem.2005.050047","volume":"51","author":"LK Kamdem","year":"2005","unstructured":"Kamdem LK, Streit F, Zanger UM, Brockmoller J, Oellerich M, Armstrong VW, et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem. 2005;51(8):1374\u201381.","journal-title":"Clin Chem"},{"issue":"2","key":"693_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/00007691-199504000-00010","volume":"17","author":"V Warty","year":"1995","unstructured":"Warty V, Zuckerman S, Venkataramanan R, Lever J, Chao J, McKaveney T, et al. Tacrolimus analysis: a comparison of different methods and matrices. Ther Drug Monit. 1995;17(2):159\u201367.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"693_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2165\/00003088-200140040-00004","volume":"40","author":"PE Wallemacq","year":"2001","unstructured":"Wallemacq PE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet. 2001;40(4):283\u201395.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"693_CR29","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2133\/dmpk.22.328","volume":"22","author":"K Iwasaki","year":"2007","unstructured":"Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet. 2007;22(5):328\u201335.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"693_CR30","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/ajm.ajm_53_20","volume":"10","author":"MZ Banday","year":"2020","unstructured":"Banday MZ, Sameer AS, Nissar S. Pathophysiology of diabetes: an overview. Avicenna J Med. 2020;10(4):174\u201388.","journal-title":"Avicenna J Med"},{"issue":"6","key":"693_CR31","first-page":"3158","volume":"23","author":"WJ Tze","year":"1991","unstructured":"Tze WJ, Tai J, Murase N, Tzakis A, Starzl TE. Effect of FK 506 on glucose metabolism and insulin secretion in normal rats. Transplant Proc. 1991;23(6):3158\u201360.","journal-title":"Transplant Proc"},{"issue":"4","key":"693_CR32","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/00007890-199204000-00033","volume":"53","author":"Y Hirano","year":"1992","unstructured":"Hirano Y, Fujihira S, Ohara K, Katsuki S, Noguchi H. Morphological and functional changes of islets of Langerhans in FK506-treated rats. Transplantation. 1992;53(4):889\u201394.","journal-title":"Transplantation"},{"issue":"2","key":"693_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/00006676-199203000-00011","volume":"7","author":"R Doi","year":"1992","unstructured":"Doi R, Tangoku A, Inoue K, Chowdhury P, Rayford PL. Effects of FK506 on exocrine pancreas in rats. Pancreas. 1992;7(2):197\u2013204.","journal-title":"Pancreas"},{"issue":"2","key":"693_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2131\/jts.19.2_61","volume":"19","author":"Y Hirano","year":"1994","unstructured":"Hirano Y, Mitamura T, Tamura T, Ohara K, Mine Y, Noguchi H. Mechanism of FK506-induced glucose intolerance in rats. J Toxicol Sci. 1994;19(2):61\u20135.","journal-title":"J Toxicol Sci"},{"issue":"3","key":"693_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0300-483X(97)00102-9","volume":"123","author":"H Ishida","year":"1997","unstructured":"Ishida H, Mitamura T, Takahashi Y, Hisatomi A, Fukuhara Y, Murato K, et al. Cataract development induced by repeated oral dosing with FK506 (tacrolimus) in adult rats. Toxicology. 1997;123(3):167\u201375.","journal-title":"Toxicology"},{"issue":"5","key":"693_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2131\/jts.23.5_403","volume":"23","author":"A Yoshida","year":"1998","unstructured":"Yoshida A, Yamamoto A, Satoh K, Ichihara K, Hoshi K. Studies of repeated administration of FK-506 on myocardial metabolism in rats. J Toxicol Sci. 1998;23(5):403\u20139.","journal-title":"J Toxicol Sci"},{"issue":"1","key":"693_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1442-9071.2005.00942.x","volume":"33","author":"Y Akar","year":"2005","unstructured":"Akar Y, Yucel G, Durukan A, Yucel I, Arici G. Systemic toxicity of tacrolimus given by various routes and the response to dose reduction. Clin Exp Ophthalmol. 2005;33(1):53\u20139.","journal-title":"Clin Exp Ophthalmol"},{"issue":"4","key":"693_CR38","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/01.tp.0000229384.22217.15","volume":"82","author":"J Larsen","year":"2006","unstructured":"Larsen J, Bennett R, Burkman T, Ramirez A, Yamamoto S, Gulizia J, et al. Tacrolimus and sirolimus cause insulin resistance in normal sprague dawley rats. Transplantation. 2006;82(4):466\u201370.","journal-title":"Transplantation"},{"issue":"11","key":"693_CR39","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1111\/j.1600-6143.2007.01946.x","volume":"7","author":"I Hernandez-Fisac","year":"2007","unstructured":"Hernandez-Fisac I, Pizarro-Delgado J, Calle C, Marques M, Sanchez A, Barrientos A, et al. Tacrolimus-induced diabetes in rats courses with suppressed insulin gene expression in pancreatic islets. Am J Transplant. 2007;7(11):2455\u201362.","journal-title":"Am J Transplant"},{"issue":"4","key":"693_CR40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1590\/S1806-83242007000400002","volume":"21","author":"CA Nassar","year":"2007","unstructured":"Nassar CA, Nassar PO, Andia DC, Guimaraes MR, Pepato MT, Spolidorio LC. Biochemical evaluation of glycemic levels of long-term tacrolimus therapy in rats. Braz Oral Res. 2007;21(4):293\u20137.","journal-title":"Braz Oral Res"},{"issue":"5","key":"693_CR41","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2131\/jts.33.575","volume":"33","author":"T Mitamura","year":"2008","unstructured":"Mitamura T, Yamada A, Hanaoka K, Asano M, Niwa T, Seki J. Effect of pharmacokinetic profile on the pancreatic toxicity and efficacy of tacrolimus in rats. J Toxicol Sci. 2008;33(5):575\u201384.","journal-title":"J Toxicol Sci"},{"issue":"4","key":"693_CR42","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3109\/08923970903032747","volume":"31","author":"QY Li","year":"2009","unstructured":"Li QY, Li F, Sun JH, Chi YY, Yin HS, Liu SQ, et al. Mechanisms of diabetes mellitus induced with FK506 in SD rats models. Immunopharmacol Immunotoxicol. 2009;31(4):675\u201381.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"3","key":"693_CR43","first-page":"60","volume":"15","author":"M Malinowski","year":"2010","unstructured":"Malinowski M, Pratschke J, Lock J, Neuhaus P, Stockmann M. Effect of tacrolimus dosing on glucose metabolism in an experimental rat model. Ann Transplant. 2010;15(3):60\u20135.","journal-title":"Ann Transplant"},{"issue":"3","key":"693_CR44","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s12020-010-9332-6","volume":"37","author":"V Shivaswamy","year":"2010","unstructured":"Shivaswamy V, McClure M, Passer J, Frahm C, Ochsner L, Erickson J, et al. Hyperglycemia induced by tacrolimus and sirolimus is reversible in normal sprague-dawley rats. Endocrine. 2010;37(3):489\u201396.","journal-title":"Endocrine"},{"issue":"2","key":"693_CR45","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3109\/08923970903358191","volume":"32","author":"F Li","year":"2010","unstructured":"Li F, Li Q. Effects of different dose of FK506 on endocrine function of pancreatic islets and damage of beta cells of pancreatic islets in a Wistar rat model. Immunopharmacol Immunotoxicol. 2010;32(2):333\u20138.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"2","key":"693_CR46","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1432-2277.2010.01167.x","volume":"24","author":"M Malinowski","year":"2011","unstructured":"Malinowski M, Martus P, Lock JF, Neuhaus P, Stockmann M. Systemic influence of immunosuppressive drugs on small and large bowel transport and barrier function. Transpl Int. 2011;24(2):184\u201393.","journal-title":"Transpl Int"},{"issue":"3","key":"693_CR47","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3109\/08923973.2011.618135","volume":"34","author":"H Hwang","year":"2012","unstructured":"Hwang H, Ghee JY, Song JH, Piao S, Yang CW. Comparison of adverse drug reaction profiles of two tacrolimus formulations in rats. Immunopharmacol Immunotoxicol. 2012;34(3):434\u201342.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"2","key":"693_CR48","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/TP.0b013e318275a322","volume":"95","author":"V Shivaswamy","year":"2013","unstructured":"Shivaswamy V, Bennett RG, Clure CC, Larsen JL, Hamel FG. Metformin improves immunosuppressant induced hyperglycemia and exocrine apoptosis in rats. Transplantation. 2013;95(2):280\u20134.","journal-title":"Transplantation"},{"issue":"7\u20138","key":"693_CR49","first-page":"869","volume":"59","author":"YJ Niu","year":"2013","unstructured":"Niu YJ, Shen ZY, Xu C, Li CF, Liu XJ, Teng YQ, et al. Establishment of tacrolimus-induced diabetes in rat model and assessment of clinical treatments for post-transplant diabetes mellitus in liver transplant recipients. Clin Lab. 2013;59(7\u20138):869\u201374.","journal-title":"Clin Lab"},{"issue":"7","key":"693_CR50","first-page":"620","volume":"52","author":"C Xu","year":"2014","unstructured":"Xu C, Niu YJ, Liu XJ, Teng YQ, Li CF, Wang HY, et al. Tacrolimus reversibly reduces insulin secretion, induces insulin resistance, and causes islet cell damage in rats. Int J Clin Pharmacol Ther. 2014;52(7):620\u20137.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"693_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100798","volume":"9","author":"L Jin","year":"2014","unstructured":"Jin L, Lim SW, Doh KC, Piao SG, Jin J, Heo SB, et al. Dipeptidyl peptidase IV inhibitor MK-0626 attenuates pancreatic islet injury in tacrolimus-induced diabetic rats. PLoS One. 2014;9(6): e100798.","journal-title":"PLoS One"},{"issue":"1","key":"693_CR52","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/TP.0000000000000146","volume":"98","author":"SG Piao","year":"2014","unstructured":"Piao SG, Lim SW, Doh KC, Jin L, Heo SB, Zheng YF, et al. Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions. Transplantation. 2014;98(1):22\u20138.","journal-title":"Transplantation"},{"key":"693_CR53","doi-asserted-by":"publisher","first-page":"29921","DOI":"10.1038\/srep29921","volume":"6","author":"SW Lim","year":"2016","unstructured":"Lim SW, Jin L, Jin J, Yang CW. Effect of exendin-4 on autophagy clearance in beta cell of rats with tacrolimus-induced diabetes mellitus. Sci Rep. 2016;6:29921.","journal-title":"Sci Rep"},{"issue":"10","key":"693_CR54","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1111\/ajt.14316","volume":"17","author":"J Jin","year":"2017","unstructured":"Jin J, Jin L, Luo K, Lim SW, Chung BH, Yang CW. Effect of empagliflozin on tacrolimus-induced pancreas islet dysfunction and renal injury. Am J Transplant. 2017;17(10):2601\u201316.","journal-title":"Am J Transplant"},{"issue":"2","key":"693_CR55","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3904\/kjim.2015.394","volume":"32","author":"J Jin","year":"2017","unstructured":"Jin J, Lim SW, Jin L, Yu JH, Kim HS, Chung BH, et al. Effects of metformin on hyperglycemia in an experimental model of tacrolimus- and sirolimus-induced diabetic rats. Korean J Intern Med. 2017;32(2):314\u201322.","journal-title":"Korean J Intern Med"},{"issue":"1","key":"693_CR56","doi-asserted-by":"publisher","first-page":"10277","DOI":"10.1038\/s41598-017-10471-2","volume":"7","author":"M Bhat","year":"2017","unstructured":"Bhat M, Pasini E, Copeland J, Angeli M, Husain S, Kumar D, et al. Impact of immunosuppression on the metagenomic composition of the intestinal microbiome: a systems biology approach to post-transplant diabetes. Sci Rep. 2017;7(1):10277.","journal-title":"Sci Rep"},{"issue":"4","key":"693_CR57","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1097\/TP.0000000000002048","volume":"102","author":"L Jin","year":"2018","unstructured":"Jin L, Lim SW, Jin J, Luo K, Ko EJ, Chung BH, et al. Effect of conversion to CTLA4Ig on tacrolimus-induced diabetic rats. Transplantation. 2018;102(4):e137\u201346.","journal-title":"Transplantation"},{"issue":"1","key":"693_CR58","doi-asserted-by":"publisher","first-page":"7995","DOI":"10.1038\/s41598-019-44475-x","volume":"9","author":"K Luo","year":"2019","unstructured":"Luo K, Yu J, Quan Y, Shin Y, Lee K, Kim H, et al. Therapeutic potential of coenzyme Q in mitochondrial dysfunction during tacrolimus-induced beta cell injury. Sci Rep. 2019;9(1):7995.","journal-title":"Sci Rep"},{"issue":"4","key":"693_CR59","first-page":"1495","volume":"44","author":"L Zhang","year":"2019","unstructured":"Zhang L, He Y, Wu C, Wu M, Chen X, Luo J, et al. Altered expression of glucose metabolism associated genes in a tacrolimus-induced post-transplantation diabetes mellitus in rat model. Int J Mol Med. 2019;44(4):1495\u2013504.","journal-title":"Int J Mol Med"},{"issue":"6","key":"693_CR60","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3904\/kjim.2019.269","volume":"35","author":"Y Quan","year":"2020","unstructured":"Quan Y, Luo K, Cui S, Lim SW, Shin YJ, Ko EJ, et al. The therapeutic efficacy of water-soluble coenzyme Q10 in an experimental model of tacrolimus-induced diabetes mellitus. Korean J Intern Med. 2020;35(6):1443\u201356.","journal-title":"Korean J Intern Med"},{"key":"693_CR61","doi-asserted-by":"publisher","first-page":"6542346","DOI":"10.1155\/2020\/6542346","volume":"2020","author":"C Zheng","year":"2020","unstructured":"Zheng C, Wang C, Zhang T, Li D, Ni XF, Lin JH, et al. Exploring the mechanism of skeletal muscle in a tacrolimus-induced posttransplantation diabetes mellitus model on gene expression profiles. J Diabetes Res. 2020;2020:6542346.","journal-title":"J Diabetes Res"},{"key":"693_CR62","doi-asserted-by":"publisher","first-page":"6613786","DOI":"10.1155\/2021\/6613786","volume":"2021","author":"N Fatima","year":"2021","unstructured":"Fatima N, Sheikh N, Satoskar A, Akhtar T, Tayyeb A, Ashfaq I, et al. Effect of short-term tacrolimus exposure on rat liver: an insight into serum antioxidant status, liver lipid peroxidation, and inflammation. Mediat. Inflamm. 2021;2021:6613786.","journal-title":"Mediat. Inflamm"},{"issue":"6","key":"693_CR63","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1111\/ajt.17035","volume":"22","author":"EJ Ko","year":"2022","unstructured":"Ko EJ, Shin YJ, Cui S, Lim SW, Chung BH, Yang CW. Effect of dual inhibition of DPP4 and SGLT2 on tacrolimus-induced diabetes mellitus and nephrotoxicity in a rat model. Am J Transplant. 2022;22(6):1537\u201349.","journal-title":"Am J Transplant"},{"issue":"1","key":"693_CR64","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/19382014.2022.2051991","volume":"14","author":"JC Quintana-Perez","year":"2022","unstructured":"Quintana-Perez JC, Garcia-Dolores F, Valdez-Guerrero AS, Aleman-Gonzalez-Duhart D, Arellano-Mendoza MG, Rojas Hernandez S, et al. Modeling type 2 diabetes in rats by administering tacrolimus. Islets. 2022;14(1):114\u201327.","journal-title":"Islets"},{"issue":"1","key":"693_CR65","first-page":"9","volume":"18","author":"FA Bakhdar","year":"2023","unstructured":"Bakhdar FA, Abdel Kawy HS, Magadmi RM, El-Kordy EA, Alamri AS. Effect of histone deacetylase inhibitor (vorinostat) on new-onset diabetes induced by tacrolimus. J Taibah Univ Med Sci. 2023;18(1):9\u201318.","journal-title":"J Taibah Univ Med Sci"},{"key":"693_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116125","volume":"171","author":"X Chen","year":"2024","unstructured":"Chen X, Hu K, Shi HZ, Zhang YJ, Chen L, He SM, et al. Syk\/BLNK\/NF-kappaB signaling promotes pancreatic injury induced by tacrolimus and potential protective effect from rapamycin. Biomed Pharmacother. 2024;171: 116125.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"693_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143405","volume":"10","author":"Z Li","year":"2015","unstructured":"Li Z, Sun F, Zhang Y, Chen H, He N, Chen H, et al. Tacrolimus induces insulin resistance and increases the glucose absorption in the jejunum: a potential mechanism of the diabetogenic effects. PLoS One. 2015;10(11): e0143405.","journal-title":"PLoS One"},{"issue":"11","key":"693_CR68","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/labinvest.2017.75","volume":"97","author":"SW Lim","year":"2017","unstructured":"Lim SW, Jin L, Luo K, Jin J, Yang CW. Ginseng extract reduces tacrolimus-induced oxidative stress by modulating autophagy in pancreatic beta cells. Lab Investig. 2017;97(11):1271\u201381.","journal-title":"Lab Investig"},{"issue":"4","key":"693_CR69","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11684-019-0686-8","volume":"13","author":"Y Han","year":"2019","unstructured":"Han Y, Jiang X, Ling Q, Wu L, Wu P, Tang R, et al. Antibiotics-mediated intestinal microbiome perturbation aggravates tacrolimus-induced glucose disorders in mice. Front Med. 2019;13(4):471\u201381.","journal-title":"Front Med"},{"issue":"1","key":"693_CR70","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s12967-019-02170-5","volume":"17","author":"L Li","year":"2019","unstructured":"Li L, Zhao H, Chen B, Fan Z, Li N, Yue J, et al. FXR activation alleviates tacrolimus-induced post-transplant diabetes mellitus by regulating renal gluconeogenesis and glucose uptake. J Transl Med. 2019;17(1):418.","journal-title":"J Transl Med"},{"issue":"9","key":"693_CR71","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1111\/ajt.15880","volume":"20","author":"W Jiao","year":"2020","unstructured":"Jiao W, Zhang Z, Xu Y, Gong L, Zhang W, Tang H, et al. Butyric acid normalizes hyperglycemia caused by the tacrolimus-induced gut microbiota. Am J Transplant. 2020;20(9):2413\u201324.","journal-title":"Am J Transplant"},{"issue":"3","key":"693_CR72","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/ajt.15665","volume":"20","author":"Q Ling","year":"2020","unstructured":"Ling Q, Huang H, Han Y, Zhang C, Zhang X, Chen K, et al. The tacrolimus-induced glucose homeostasis imbalance in terms of the liver: from bench to bedside. Am J Transplant. 2020;20(3):701\u201313.","journal-title":"Am J Transplant"},{"issue":"12","key":"693_CR73","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1111\/bph.15803","volume":"179","author":"S Li","year":"2022","unstructured":"Li S, Zhou H, Xie M, Zhang Z, Gou J, Yang J, et al. Regenerating islet-derived protein 3 gamma (Reg3g) ameliorates tacrolimus-induced pancreatic beta-cell dysfunction in mice by restoring mitochondrial function. Br J Pharmacol. 2022;179(12):3078\u201395.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"693_CR74","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40360-022-00626-x","volume":"23","author":"D Xie","year":"2022","unstructured":"Xie D, Guo J, Dang R, Li Y, Si Q, Han W, et al. The effect of tacrolimus-induced toxicity on metabolic profiling in target tissues of mice. BMC Pharmacol Toxicol. 2022;23(1):87.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"693_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15536","volume":"9","author":"Z Li","year":"2023","unstructured":"Li Z, Xiang J, Mei S, Wu Y, Xu Y. The effect of PINK1\/Parkin pathway on glucose homeostasis imbalance induced by tacrolimus in mouse livers. Heliyon. 2023;9(4): e15536.","journal-title":"Heliyon"},{"issue":"3","key":"693_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1081","volume":"11","author":"X Sun","year":"2023","unstructured":"Sun X, Wang H, Chi J, Che K, Wang Y. Endoplasmic reticulum stress in the adipose tissue and monocyte chemoattractant protein-1 are involved in tacrolimus-induced diabetes mellitus. Pharmacol Res Perspect. 2023;11(3): e01081.","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"693_CR77","doi-asserted-by":"publisher","first-page":"2310277","DOI":"10.1080\/19490976.2024.2310277","volume":"16","author":"P Li","year":"2024","unstructured":"Li P, Zhang R, Zhou J, Guo P, Liu Y, Shi S. Vancomycin relieves tacrolimus-induced hyperglycemia by eliminating gut bacterial beta-glucuronidase enzyme activity. Gut Microbes. 2024;16(1):2310277.","journal-title":"Gut Microbes"},{"issue":"2\u20133","key":"693_CR78","first-page":"241","volume":"93","author":"CG Ostenson","year":"1989","unstructured":"Ostenson CG, Grill V, Roos M. Studies on sex dependency of B-cell susceptibility to streptozotocin in a rat model of type II diabetes mellitus. Exp Clin Endocrinol. 1989;93(2\u20133):241\u20137.","journal-title":"Exp Clin Endocrinol"},{"issue":"2 Pt 2","key":"693_CR79","first-page":"R725","volume":"273","author":"BE Levin","year":"1997","unstructured":"Levin BE, Dunn-Meynell AA, Balkan B, Keesey RE. Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats. Am J Physiol. 1997;273(2 Pt 2):R725\u2013R730.","journal-title":"Am J Physiol"},{"issue":"9","key":"693_CR80","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.2337\/diab.37.9.1163","volume":"37","author":"RS Surwit","year":"1988","unstructured":"Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN. Diet-induced type II diabetes in C57BL\/6J mice. Diabetes. 1988;37(9):1163\u20137.","journal-title":"Diabetes"},{"issue":"Suppl 3","key":"693_CR81","doi-asserted-by":"publisher","first-page":"S215","DOI":"10.2337\/diabetes.53.suppl_3.S215","volume":"53","author":"MS Winzell","year":"2004","unstructured":"Winzell MS, Ahren B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes. 2004;53(Suppl 3):S215\u2013S219.","journal-title":"Diabetes"},{"issue":"6","key":"693_CR82","first-page":"42","volume":"43","author":"JP Balcombe","year":"2004","unstructured":"Balcombe JP, Barnard ND, Sandusky C. Laboratory routines cause animal stress. Contemp Top Lab Anim Sci. 2004;43(6):42\u201351.","journal-title":"Contemp Top Lab Anim Sci"},{"issue":"1","key":"693_CR83","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11095-019-2745-x","volume":"37","author":"A Al Shoyaib","year":"2019","unstructured":"Al Shoyaib A, Archie SR, Karamyan VT. Intraperitoneal route of drug administration: should it be used in experimental animal studies? Pharm Res. 2019;37(1):12.","journal-title":"Pharm Res"},{"issue":"3","key":"693_CR84","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1248\/yakushi.14-00161","volume":"135","author":"T Yamada","year":"2015","unstructured":"Yamada T. Pharmacological study and pharmaceutical intervention to reduce intravenous injection-induced vascular injury. Yakugaku Zasshi. 2015;135(3):465\u201372.","journal-title":"Yakugaku Zasshi"},{"issue":"11","key":"693_CR85","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","volume":"36","author":"I Usach","year":"2019","unstructured":"Usach I, Martinez R, Festini T, Peris JE. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36(11):2986\u201396.","journal-title":"Adv Ther"},{"issue":"9","key":"693_CR86","first-page":"965","volume":"34","author":"CB Tuttle","year":"1977","unstructured":"Tuttle CB. Intramuscular injections and bioavailability. Am J Hosp Pharm. 1977;34(9):965\u20138.","journal-title":"Am J Hosp Pharm"},{"issue":"6","key":"693_CR87","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2217\/pgs-2018-0003","volume":"19","author":"AL Pasternak","year":"2018","unstructured":"Pasternak AL, Zhang L, Hertz DL. CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration. Pharmacogenomics. 2018;19(6):563\u201376.","journal-title":"Pharmacogenomics"},{"issue":"3","key":"693_CR88","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s12325-016-0295-8","volume":"33","author":"G Bianchi","year":"2016","unstructured":"Bianchi G, Caporali R, Todoerti M, Mattana P. Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration. Adv Ther. 2016;33(3):369\u201378.","journal-title":"Adv Ther"},{"issue":"2\u20133","key":"693_CR89","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0300-483X(97)00167-4","volume":"125","author":"KW Mollison","year":"1998","unstructured":"Mollison KW, Fey TA, Krause RA, Andrews JM, Bretheim PT, Cusick PK, et al. Nephrotoxicity studies of the immunosuppressants tacrolimus (FK506) and ascomycin in rat models. Toxicology. 1998;125(2\u20133):169\u201381.","journal-title":"Toxicology"},{"issue":"7","key":"693_CR90","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/ajt.12236","volume":"13","author":"AE Rodriguez-Rodriguez","year":"2013","unstructured":"Rodriguez-Rodriguez AE, Trinanes J, Velazquez-Garcia S, Porrini E, Vega Prieto MJ, Diez Fuentes ML, et al. The higher diabetogenic risk of tacrolimus depends on pre-existing insulin resistance. A study in obese and lean Zucker rats. Am J Transplant. 2013;13(7):1665\u201375.","journal-title":"Am J Transplant"},{"key":"693_CR91","doi-asserted-by":"publisher","first-page":"1388361","DOI":"10.3389\/fendo.2024.1388361","volume":"15","author":"S Teixido-Trujillo","year":"2024","unstructured":"Teixido-Trujillo S, Porrini E, Menendez-Quintanal LM, Torres-Ramirez A, Fumero C, Rodriguez-Rodriguez AE. Induction of diabetes by Tacrolimus in a phenotypic model of obesity and metabolic syndrome. Front Endocrinol (Lausanne). 2024;15:1388361.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"693_CR92","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1248\/yakushi.127.1883","volume":"127","author":"Y Tayama","year":"2007","unstructured":"Tayama Y, Miyake K, Nagafuji T, Gouhara T, Morita S, Arai S, et al. Influence of tacrolimus and ciprofloxacin on glucose metabolism. Yakugaku Zasshi. 2007;127(11):1883\u20139.","journal-title":"Yakugaku Zasshi"},{"issue":"8","key":"693_CR93","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrneph.2015.59","volume":"11","author":"T Jenssen","year":"2015","unstructured":"Jenssen T, Hartmann A. Emerging treatments for post-transplantation diabetes mellitus. Nat Rev Nephrol. 2015;11(8):465\u201377.","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"693_CR94","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1111\/ajt.14323","volume":"17","author":"J Trinanes","year":"2017","unstructured":"Trinanes J, Rodriguez-Rodriguez AE, Brito-Casillas Y, Wagner A, De Vries APJ, Cuesto G, et al. Deciphering tacrolimus-induced toxicity in pancreatic beta cells. Am J Transplant. 2017;17(11):2829\u201340.","journal-title":"Am J Transplant"},{"issue":"8","key":"693_CR95","doi-asserted-by":"publisher","first-page":"eaax2358","DOI":"10.1126\/sciadv.aax2358","volume":"5","author":"MR Taylor","year":"2019","unstructured":"Taylor MR, Flannigan KL, Rahim H, Mohamud A, Lewis IA, Hirota SA, et al. Vancomycin relieves mycophenolate mofetil-induced gastrointestinal toxicity by eliminating gut bacterial beta-glucuronidase activity. Sci Adv. 2019;5(8):eaax2358.","journal-title":"Sci Adv"},{"issue":"19","key":"693_CR96","doi-asserted-by":"publisher","first-page":"10311","DOI":"10.3390\/ijms221910311","volume":"22","author":"AE Rodriguez-Rodriguez","year":"2021","unstructured":"Rodriguez-Rodriguez AE, Porrini E, Torres A. Beta-cell dysfunction induced by tacrolimus: a way to explain type 2 diabetes? Int J Mol Sci. 2021;22(19):10311.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"693_CR97","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.intimp.2011.05.023","volume":"11","author":"XM Qi","year":"2011","unstructured":"Qi XM, Wu YG, Liang C, Zhang P, Dong J, Ren KJ, et al. FK506 ameliorates renal injury in early experimental diabetic rats induced by streptozotocin. Int Immunopharmacol. 2011;11(10):1613\u20139.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"693_CR98","first-page":"14063","volume":"8","author":"R Ma","year":"2015","unstructured":"Ma R, Liu L, Jiang W, Yu Y, Song H. FK506 ameliorates podocyte injury in type 2 diabetic nephropathy by down-regulating TRPC6 and NFAT expression. Int J Clin Exp Pathol. 2015;8(11):14063\u201374.","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"693_CR99","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00011-015-0893-y","volume":"65","author":"XM Qi","year":"2016","unstructured":"Qi XM, Wang J, Xu XX, Li YY, Wu YG. FK506 reduces albuminuria through improving podocyte nephrin and podocin expression in diabetic rats. Inflamm Res. 2016;65(2):103\u201314.","journal-title":"Inflamm Res"},{"key":"693_CR100","doi-asserted-by":"publisher","first-page":"8832114","DOI":"10.1155\/2021\/8832114","volume":"2021","author":"R Ma","year":"2021","unstructured":"Ma R, Wang Y, Xu Y, Wang R, Wang X, Yu N, et al. Tacrolimus protects podocytes from apoptosis via downregulation of TRPC6 in diabetic nephropathy. J Diabetes Res. 2021;2021:8832114.","journal-title":"J Diabetes Res"},{"issue":"5","key":"693_CR101","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.3892\/mmr.2017.6354","volume":"15","author":"T Peng","year":"2017","unstructured":"Peng T, Chang X, Wang J, Zhen J, Yang X, Hu Z. Protective effects of tacrolimus on podocytes in early diabetic nephropathy in rats. Mol Med Rep. 2017;15(5):3172\u20138.","journal-title":"Mol Med Rep"},{"issue":"12","key":"693_CR102","doi-asserted-by":"publisher","first-page":"265","DOI":"10.21037\/atm.2019.05.44","volume":"7","author":"LH Ni","year":"2019","unstructured":"Ni LH, Tang RN, Yuan C, Song KY, Wang LT, Wang XC, et al. FK506 prevented bone loss in streptozotocin-induced diabetic rats via enhancing osteogenesis and inhibiting adipogenesis. Ann Transl Med. 2019;7(12):265.","journal-title":"Ann Transl Med"},{"issue":"2","key":"693_CR103","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s12640-019-00062-6","volume":"36","author":"YJ Shin","year":"2019","unstructured":"Shin YJ, Chun YT, Lim SW, Luo K, Quan Y, Cui S, et al. Influence of tacrolimus on depressive-like behavior in diabetic rats through brain-derived neurotrophic factor regulation in the hippocampus. Neurotox Res. 2019;36(2):396\u2013410.","journal-title":"Neurotox Res"},{"issue":"1\u20132","key":"693_CR104","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000366446","volume":"128","author":"Y Wu","year":"2014","unstructured":"Wu Y, Wang Y, Qi X, Zhang P, Zhang C, Zhang W. Increased macrophage activation inhibited by tacrolimus in the kidney of diabetic rats. Nephron Exp Nephrol. 2014;128(1\u20132):46\u201356.","journal-title":"Nephron Exp Nephrol"},{"issue":"3","key":"693_CR105","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/BF00300231","volume":"277","author":"G Papaccio","year":"1994","unstructured":"Papaccio G, Latronico M, Chieffi BG. The immunosuppressant FK506 inhibits the damage to mouse pancreatic islets induced by low dose streptozocin. Cell Tissue Res. 1994;277(3):573\u20138.","journal-title":"Cell Tissue Res"},{"issue":"1 Pt 1","key":"693_CR106","first-page":"551","volume":"23","author":"N Murase","year":"1991","unstructured":"Murase N, Lieberman I, Nalesnik M, Mintz D, Todo S, Drash AL, et al. FK 506 prevents spontaneous diabetes in the BB rat. Transplant Proc. 1991;23(1 Pt 1):551\u20135.","journal-title":"Transplant Proc"},{"issue":"7","key":"693_CR107","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/0192-0561(91)90057-E","volume":"13","author":"F Nicoletti","year":"1991","unstructured":"Nicoletti F, Meroni PL, Barcellini W, Grasso S, Borghi MO, Lunetta M, et al. FK-506 prevents diabetes in diabetes-prone BB\/Wor rats. Int J Immunopharmacol. 1991;13(7):1027\u201330.","journal-title":"Int J Immunopharmacol"},{"issue":"12","key":"693_CR108","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.2337\/diab.39.12.1584","volume":"39","author":"N Murase","year":"1990","unstructured":"Murase N, Lieberman I, Nalesnik MA, Mintz DH, Todo S, Drash AL, et al. Effect of FK 506 on spontaneous diabetes in BB rats. Diabetes. 1990;39(12):1584\u20136.","journal-title":"Diabetes"},{"issue":"1","key":"693_CR109","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1620\/tjem.169.21","volume":"169","author":"T Wakugami","year":"1993","unstructured":"Wakugami T, Islam M, Higa S, Murakami K, Mimura G. Effect of FK506 on the development of diabetes in BB rats in comparison with that of cyclosporin. Tohoku J Exp Med. 1993;169(1):21\u20139.","journal-title":"Tohoku J Exp Med"},{"issue":"3","key":"693_CR110","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.nefro.2015.05.007","volume":"35","author":"A Rodr\u00edguez-Rodr\u00edguez","year":"2015","unstructured":"Rodr\u00edguez-Rodr\u00edguez A, Tri\u00f1anes J, Porrini E, Vel\u00e1zquez-Garc\u00eda S, Fumero C, Vega-Prieto M, et al. Glucose homeostasis changes and pancreatic \u03b2-cell proliferation after switching to cyclosporin in tacrolimus-induced diabetes mellitus. Nefrologia. 2015;35(3):264\u201372.","journal-title":"Nefrologia"},{"issue":"2","key":"693_CR111","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/0090-1229(90)90041-N","volume":"57","author":"K Kurasawa","year":"1990","unstructured":"Kurasawa K, Koike T, Matsumura R, Takabayashi K, Tomioka H, Ito I, et al. The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. Clin Immunol Immunopathol. 1990;57(2):274\u20139.","journal-title":"Clin Immunol Immunopathol"},{"issue":"8","key":"693_CR112","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/BF00405113","volume":"33","author":"J Miyagawa","year":"1990","unstructured":"Miyagawa J, Yamamoto K, Hanafusa T, Itoh N, Nakagawa C, Otsuka A, et al. Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. Diabetologia. 1990;33(8):503\u20135.","journal-title":"Diabetologia"},{"issue":"4","key":"693_CR113","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/00007890-199304000-00045","volume":"55","author":"N Kai","year":"1993","unstructured":"Kai N, Motojima K, Tsunoda T, Kanematsu T. Prevention of insulitis and diabetes in nonobese diabetic mice by administration of FK506. Transplantation. 1993;55(4):936\u201340.","journal-title":"Transplantation"},{"issue":"2","key":"693_CR114","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s00125-001-0745-x","volume":"45","author":"A Shapiro","year":"2002","unstructured":"Shapiro A, Suarez-Pinzon W, Power R, Rabinovitch A. Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese diabetic mice. Diabetologia. 2002;45(2):224\u201330.","journal-title":"Diabetologia"},{"issue":"8","key":"693_CR115","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1210\/me.2011-0029","volume":"25","author":"L Wang","year":"2011","unstructured":"Wang L, Chang J, Paik S, Tang Y, Eisner W, Spurney R. Calcineurin (CN) activation promotes apoptosis of glomerular podocytes both in vitro and in vivo. Mol Endocrinol. 2011;25(8):1376\u201386.","journal-title":"Mol Endocrinol"},{"issue":"17","key":"693_CR116","doi-asserted-by":"publisher","first-page":"9810","DOI":"10.1111\/jcmm.15562","volume":"24","author":"S Zhang","year":"2020","unstructured":"Zhang S, Wang H, Liu Y, Yang W, Liu J, Han Y, et al. Tacrolimus ameliorates tubulointerstitial inflammation in diabetic nephropathy via inhibiting the NFATc1\/TRPC6 pathway. J Cell Mol Med. 2020;24(17):9810\u201324.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"693_CR117","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1440-1797.2007.00796.x","volume":"12","author":"GH Tesch","year":"2007","unstructured":"Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton). 2007;12(3):261\u20136.","journal-title":"Nephrology (Carlton)"},{"key":"693_CR118","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cbi.2015.11.032","volume":"244","author":"SN Goyal","year":"2016","unstructured":"Goyal SN, Reddy NM, Patil KR, Nakhate KT, Ojha S, Patil CR, et al. Challenges and issues with streptozotocin-induced diabetes\u2014a clinically relevant animal model to understand the diabetes pathogenesis and evaluate therapeutics. Chem Biol Interact. 2016;244:49\u201363.","journal-title":"Chem Biol Interact"},{"key":"693_CR119","doi-asserted-by":"publisher","first-page":"5.47.41","DOI":"10.1002\/0471141755.ph0547s70","volume":"70","author":"BL Furman","year":"2015","unstructured":"Furman BL. Streptozotocin-induced diabetic models in mice and rats. Curr Protoc Pharmacol. 2015;70:5.47.1\u20135.47.20.","journal-title":"Curr Protoc Pharmacol"},{"issue":"10","key":"693_CR120","first-page":"1523","volume":"117","author":"YS Zhou","year":"2004","unstructured":"Zhou YS, Gao Y, Guo XH, Li B, Wang S, Chi JM. Effects of timely insulin treatment on protection of beta cells in a rat model of type 2 diabetes mellitus. Chin Med J (Engl). 2004;117(10):1523\u20139.","journal-title":"Chin Med J (Engl)"},{"issue":"9","key":"693_CR121","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1699-0463.1996.tb04920.x","volume":"104","author":"K Buschard","year":"1996","unstructured":"Buschard K. Diabetic animal models. APMIS. 1996;104(9):609\u201314.","journal-title":"APMIS"},{"issue":"1","key":"693_CR122","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3181\/00379727-139-36078","volume":"139","author":"J Stern","year":"1972","unstructured":"Stern J, Johnson PR, Greenwood MR, Zucker LM, Hirsch J. Insulin resistance and pancreatic insulin release in the genetically obese Zucker rat. Proc Soc Exp Biol Med. 1972;139(1):66\u20139.","journal-title":"Proc Soc Exp Biol Med"},{"issue":"4","key":"693_CR123","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s00592-005-0197-8","volume":"42","author":"BL Leonard","year":"2005","unstructured":"Leonard BL, Watson RN, Loomes KM, Phillips AR, Cooper GJ. Insulin resistance in the Zucker diabetic fatty rat: a metabolic characterisation of obese and lean phenotypes. Acta Diabetol. 2005;42(4):162\u201370.","journal-title":"Acta Diabetol"},{"issue":"5","key":"693_CR124","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00281-014-0438-4","volume":"36","author":"P In\u2019t Veld","year":"2014","unstructured":"In\u2019t Veld P. Insulitis in human type 1 diabetes: a comparison between patients and animal models. Semin Immunopathol. 2014;36(5):569\u201379.","journal-title":"Semin Immunopathol"},{"key":"693_CR125","unstructured":"Leiter EH. The NOD mouse: a model for insulin-dependent diabetes mellitus. Curr Protoc Immunol. 2001;Chapter 15:15.9.1\u201315.9.23."},{"issue":"1","key":"693_CR126","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s42826-021-00101-4","volume":"37","author":"CPD Kottaisamy","year":"2021","unstructured":"Kottaisamy CPD, Raj DS, Prasanth Kumar V, Sankaran U. Experimental animal models for diabetes and its related complications-a review. Lab Anim Res. 2021;37(1):23.","journal-title":"Lab Anim Res"},{"issue":"5","key":"693_CR127","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.jmb.2019.09.016","volume":"432","author":"M Lytrivi","year":"2020","unstructured":"Lytrivi M, Castell A, Poitout V, Cnop M. Recent insights into mechanisms of \u03b2-cell lipo- and glucolipotoxicity in type 2 diabetes. J Mol Biol. 2020;432(5):1514\u201334.","journal-title":"J Mol Biol"},{"issue":"7109","key":"693_CR128","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nature05097","volume":"443","author":"J Heit","year":"2006","unstructured":"Heit J, Apelqvist A, Gu X, Winslow M, Neilson J, Crabtree G, et al. Calcineurin\/NFAT signalling regulates pancreatic beta-cell growth and function. Nature. 2006;443(7109):345\u20139.","journal-title":"Nature"},{"issue":"1","key":"693_CR129","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.devcel.2012.05.014","volume":"23","author":"WR Goodyer","year":"2012","unstructured":"Goodyer WR, Gu X, Liu Y, Bottino R, Crabtree GR, Kim SK. Neonatal beta cell development in mice and humans is regulated by calcineurin\/NFAT. Dev Cell. 2012;23(1):21\u201334.","journal-title":"Dev Cell"},{"issue":"3","key":"693_CR130","doi-asserted-by":"publisher","first-page":"235","DOI":"10.25100\/cm.v43i3.783","volume":"43","author":"N Balcazar Morales","year":"2012","unstructured":"Balcazar Morales N, Aguilar de Plata C. Role of AKT\/mTORC1 pathway in pancreatic beta-cell proliferation. Colomb Med (Cali). 2012;43(3):235\u201343.","journal-title":"Colomb Med (Cali)"},{"issue":"2","key":"693_CR131","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274\u201393.","journal-title":"Cell"},{"issue":"8","key":"693_CR132","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.cellsig.2016.05.007","volume":"28","author":"J Wang","year":"2016","unstructured":"Wang J, Yang X, Zhang J. Bridges between mitochondrial oxidative stress, ER stress and mTOR signaling in pancreatic \u03b2 cells. Cell Signal. 2016;28(8):1099\u2013104.","journal-title":"Cell Signal"},{"issue":"Suppl 1","key":"693_CR133","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.2337\/diabetes.53.2007.S119","volume":"53","author":"RP Robertson","year":"2004","unstructured":"Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes. 2004;53(Suppl 1):S119\u2013S124.","journal-title":"Diabetes"},{"issue":"6","key":"693_CR134","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00109-005-0640-x","volume":"83","author":"H Kaneto","year":"2005","unstructured":"Kaneto H, Matsuoka TA, Nakatani Y, Kawamori D, Miyatsuka T, Matsuhisa M, et al. Oxidative stress, ER stress, and the JNK pathway in type 2 diabetes. J Mol Med (Berl). 2005;83(6):429\u201339.","journal-title":"J Mol Med (Berl)"},{"issue":"11","key":"693_CR135","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1111\/ajt.14323","volume":"17","author":"J Tri\u00f1anes","year":"2017","unstructured":"Tri\u00f1anes J, Rodriguez-Rodriguez AE, Brito-Casillas Y, Wagner A, De Vries APJ, Cuesto G, et al. Deciphering tacrolimus-induced toxicity in pancreatic \u03b2 cells. Am J Transplant. 2017;17(11):2829\u201340.","journal-title":"Am J Transplant"},{"issue":"12","key":"693_CR136","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1111\/ajt.15483","volume":"19","author":"AE Rodriguez-Rodriguez","year":"2019","unstructured":"Rodriguez-Rodriguez AE, Donate-Correa J, Rovira J, Cuesto G, Luis-Ravelo D, Fernandes MX, et al. Inhibition of the mTOR pathway: a new mechanism of beta cell toxicity induced by tacrolimus. Am J Transplant. 2019;19(12):3240\u20139.","journal-title":"Am J Transplant"},{"key":"693_CR137","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jbior.2017.06.003","volume":"65","author":"MA Hermida","year":"2017","unstructured":"Hermida MA, Dinesh Kumar J, Leslie NR. GSK3 and its interactions with the PI3K\/AKT\/mTOR signalling network. Adv Biol Regul. 2017;65:5\u201315.","journal-title":"Adv Biol Regul"},{"key":"693_CR138","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/1479-5876-10-183","volume":"10","author":"L Kubiczkova","year":"2012","unstructured":"Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-beta\u2014an excellent servant but a bad master. J Transl Med. 2012;10:183.","journal-title":"J Transl Med"},{"issue":"3","key":"693_CR139","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/biom10030487","volume":"10","author":"K Tzavlaki","year":"2020","unstructured":"Tzavlaki K, Moustakas A. TGF-beta signaling. Biomolecules. 2020;10(3):487.","journal-title":"Biomolecules"},{"key":"693_CR140","doi-asserted-by":"publisher","first-page":"16009","DOI":"10.1038\/boneres.2016.9","volume":"4","author":"M Wu","year":"2016","unstructured":"Wu M, Chen G, Li YP. TGF-beta and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res. 2016;4:16009.","journal-title":"Bone Res"},{"issue":"3","key":"693_CR141","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0092-8674(00)80116-6","volume":"86","author":"T Wang","year":"1996","unstructured":"Wang T, Li BY, Danielson PD, Shah PC, Rockwell S, Lechleider RJ, et al. The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell. 1996;86(3):435\u201344.","journal-title":"Cell"},{"issue":"13","key":"693_CR142","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.1093\/emboj\/16.13.3866","volume":"16","author":"YG Chen","year":"1997","unstructured":"Chen YG, Liu F, Massague J. Mechanism of TGFbeta receptor inhibition by FKBP12. EMBO J. 1997;16(13):3866\u201376.","journal-title":"EMBO J"},{"issue":"17","key":"693_CR143","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.1093\/emboj\/16.17.5353","volume":"16","author":"A Nakao","year":"1997","unstructured":"Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, et al. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 1997;16(17):5353\u201362.","journal-title":"EMBO J"},{"issue":"11","key":"693_CR144","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a022111","volume":"8","author":"A Chaikuad","year":"2016","unstructured":"Chaikuad A, Bullock AN. Structural basis of intracellular TGF-beta signaling: receptors and smads. Cold Spring Harb Perspect Biol. 2016;8(11): a022111.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2","key":"693_CR145","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2337\/db19-0828","volume":"69","author":"J Tri\u00f1anes","year":"2020","unstructured":"Tri\u00f1anes J, Ten Dijke P, Groen N, Hanegraaf M, Porrini E, Rodriguez-Rodriguez A, et al. Tacrolimus-induced BMP\/SMAD signaling associates with metabolic stress-activated FOXO1 to trigger \u03b2-cell failure. Diabetes. 2020;69(2):193\u2013204.","journal-title":"Diabetes"},{"issue":"6","key":"693_CR146","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1074\/jbc.M115.704098","volume":"291","author":"T Speckmann","year":"2016","unstructured":"Speckmann T, Sabatini PV, Nian C, Smith RG, Lynn FC. Npas4 transcription factor expression is regulated by calcium signaling pathways and prevents tacrolimus-induced cytotoxicity in pancreatic beta cells. J Biol Chem. 2016;291(6):2682\u201395.","journal-title":"J Biol Chem"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-024-00693-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-024-00693-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-024-00693-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T12:59:52Z","timestamp":1742216392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-024-00693-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":146,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["693"],"URL":"https:\/\/doi.org\/10.1007\/s43440-024-00693-3","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"type":"print","value":"1734-1140"},{"type":"electronic","value":"2299-5684"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}